Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

被引：3
作者：
Elshaer, Amani [1 ]
Chascsa, David M. H. [2 ,3 ]
Lizaola-Mayo, Blanca C. [2 ,3 ]
机构：
[1] Mayo Clin, Dept Internal Med, Scottsdale, AZ 85054 USA
[2] Mayo Clin, Div Gastroenterol & Hepatol, Scottsdale, AZ 85054 USA
[3] Mayo Clin, Transplant Ctr, Dept Med, Scottsdale, AZ 85054 USA
来源：
LIFE-BASEL | 2024年 / 14卷 / 07期
关键词：
metabolic-associated steatotic liver disease; fibrosis; cirrhosis; obesity; weight loss; lifestyle modification; pharmacotherapy; bariatric surgery; LIFE-STYLE MODIFICATION; CLINICAL-PRACTICE UPDATE; GLUCAGON-LIKE PEPTIDE-1; CORONARY-HEART-DISEASE; FATTY LIVER; BARIATRIC SURGERY; INSULIN-RESISTANCE; WEIGHT-LOSS; NONALCOHOLIC STEATOHEPATITIS; AMERICAN ASSOCIATION;
D O I：
10.3390/life14070844
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a liver disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading to increased patient risk of various complications. Recent research has been focused on new therapeutic strategies to reduce the incidence of MASLD and provide effective treatment plans to prevent further irreversible liver damage. The treatment approach is multifactorial, with a primary focus on weight loss and management of underlying comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing research is exploring new pharmacological therapies that could enhance the treatment of MASLD.
引用
收藏
页数：21
相关论文
共 50 条
  • [41] Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population
    Chew, Nicholas W. S.
    Pan, Xin Hui
    Chong, Bryan
    Chandramouli, Chanchal
    Muthiah, Mark
    Lam, Carolyn S. P.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 211
  • [42] Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
    Ding, Yuping
    Deng, Quanjun
    Yang, Mei
    Niu, Haiyan
    Wang, Zuoyu
    Xia, Shihai
    DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 3303 - 3329
  • [43] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [44] NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Kaylan, Kerim B.
    Paul, Sonali
    CURRENT DIABETES REPORTS, 2025, 25 (01)
  • [45] Myokines and Their Potential Protective Role Against Oxidative Stress in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Bucarey, Jose Luis
    Trujillo-Gonzalez, Isis
    Paules, Evan M.
    Espinosa, Alejandra
    ANTIOXIDANTS, 2024, 13 (11)
  • [46] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [47] Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease
    van Dijk, A. M.
    de Vries, M.
    El-Morabit, F.
    Bac, S. T.
    Mundt, M. W.
    van der Schuit, L. E.
    Hirdes, M. M. C.
    Kara, M.
    de Bruijne, J.
    van Meer, S.
    Kaasjager, H. A. H.
    de Valk, H. W.
    Vleggaar, F. P.
    van Erpecum, K. J.
    INTERNAL AND EMERGENCY MEDICINE, 2023, 18 (08) : 2271 - 2280
  • [48] The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
    Paklar, Natasa
    Mijic, Maja
    Filipec-Kanizaj, Tajana
    BIOMEDICINES, 2023, 11 (11)
  • [49] Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective
    Wang, Ming-Wang
    Lu, Lun-Gen
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2025, 13 (01) : 47 - 61
  • [50] The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease
    Heymann, Clement J. F.
    Mak, Anne Linde
    Holleboom, Adriaan G.
    Verheij, Joanne
    Shiri-Sverdlov, Ronit
    van Mil, Saskia W. C.
    Tushuizen, Maarten E.
    Koek, Ger H.
    Grefhorst, Aldo
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
12345